Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.
Saved in:
| Title: | Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. |
|---|---|
| Authors: | Barroso-Sousa R; Oncology Center, Hospital Sírio-Libanês Brasília, Brasília, Brazil., Tarantino P; European Institute of Oncology IRCCS, Milan, Italy.; University of Milan, Milan, Italy.; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tayob N; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Dang C; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Yardley DA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA., Isakoff SJ; Massachusetts General Hospital, Boston, MA, USA., Valero V; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Faggen M; Dana-Farber Cancer Institute, Boston, MA, USA., Mulvey T; Massachusetts General Hospital, Boston, MA, USA., Bose R; Washington University, St Louis, MO, USA., Hu J; Dana-Farber Cancer Institute, Boston, MA, USA., Weckstein D; Dana-Farber Cancer Institute, Boston, MA, USA., Wolff AC; Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA., Reeder-Hayes K; UNC Chapel Hill, Chapel Hill, NC, USA., Rugo HS; UCSF, San Francisco, CA, USA., Ramaswamy B; OSU Comprehensive Cancer Center, Columbus, OH, USA., Zuckerman D; St Luke's Mountain States Tumor Institute, Boise, ID, USA., Hart L; Wake Forest Baptist Health, Winston-Salem, NC, USA., Gadi VK; University of Washington, Seattle, WA, USA.; Vijayakrishna K. Gadi's current affiliation is University of Illinois at Chicago, Chicago, IL, USA., Constantine M; Dana-Farber Cancer Institute, Boston, MA, USA., Cheng K; North Shore-LIJ Cancer Institute, Lake Success, NY, USA., Briccetti F; Dana-Farber Cancer Institute, Boston, MA, USA., Schneider B; IU School of Medicine, Indianapolis, IN, USA., Garrett AM; Northern Light Cancer Care, Brewer, ME, USA., Marcom K; Duke University, Durham, NC, USA., Albain K; Loyola University Medical Center, Maywood, IL, USA., DeFusco P; Hartford Healthcare Cancer Institute, Hartford, CT, USA., Tung N; Harvard Medical School, Boston, MA, USA.; Beth Israel Deaconess Medical Center, Boston, MA, USA., Ardman B; Lowell General Hospital, Lowell, MA, USA., Nanda R; The University of Chicago, Chicago, IL, USA., Jankowitz RC; Abramsom Cancer Center, University of Pennsylvania, Philadelphia, PA, USA., Rimawi M; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA., Abramson V; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Pohlmann PR; Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, USA., Van Poznak C; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA., Forero-Torres A; Kirklin UAB Hematology Oncology, Birmingham, AL, USA., Liu M; Mayo Clinic, Rochester, MN, USA., Ruddy KJ; Mayo Clinic, Rochester, MN, USA., Zheng Y; Dana-Farber Cancer Institute, Boston, MA, USA., Rosenberg SM; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA.; Weill Cornell Medicine, New York, NY, USA., Gelber RD; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Trippa L; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Barry W; Dana-Farber Cancer Institute, Boston, MA, USA., DeMeo M; Dana-Farber Cancer Institute, Boston, MA, USA., Burstein H; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Partridge A; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Winer EP; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Krop I; Dana-Farber Cancer Institute, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Tolaney SM; Dana-Farber Cancer Institute, Boston, MA, USA. Sara_Tolaney@DFCI.HARVARD.EDU.; Harvard Medical School, Boston, MA, USA. Sara_Tolaney@DFCI.HARVARD.EDU. |
| Source: | NPJ breast cancer [NPJ Breast Cancer] 2022 Feb 16; Vol. 8 (1), pp. 18. Date of Electronic Publication: 2022 Feb 16. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
